Tingrui Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tingrui Zhao has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Chao Yu
Chongqing Medical University
1 shared publication Jing Chen
Department of Clinical Pharmacy, The Third Hospital of Mianyang (Sichuan Mental Health Center), Mianyang, Sichuan, People’s Republic of China
1 shared publicationJing Li
Department of Neurology, Mianyang people’s Hospital, Mianyang, Sichuan, People’s Republic of China
1 shared publication- Jisheng Wang
Department of Clinical Pharmacy, The Third Hospital of Mianyang (Sichuan Mental Health Center), Mianyang, Sichuan, People’s Republic of China
1 shared publication Qingsong Jiang
College of Pharmacy, Chongqing Medical University, Chongqing, People’s Republic of China
1 shared publicationSiyi Liu
College of Pharmacy, Chongqing Medical University, Chongqing, People’s Republic of China
1 shared publication
Latest Publications
- Open Access
- 3 July 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (27) , e49670
Comprehensive analysis of factors to consider when using glucocorticoids for sCAP: A review
Severe community-acquired pneumonia (sCAP) is a serious respiratory disease that often requires urgent and comprehensive treatment. The use of glucocorticoids for the treatment of sCAP has been a focus of discussion in the medical community because of their potential benefits and safety concerns. A literature review showed that the benefits of glucocorticoids in the treatment of sCAP may be related to factors such as oxygenation index, high CRP levels, shock, non-influenza, female gender, early application, and hydrocortisone. The application of glucocorticoids in the treatment of sCAP needs to be considered on an individual basis, weighing the potential benefits and risks, and monitoring and preventing possible side effects.
- 3 July 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (27) , e49670
Open AccessComprehensive analysis of factors to consider when using glucocorticoids for sCAP: A review
Severe community-acquired pneumonia (sCAP) is a serious respiratory disease that often requires urgent and comprehensive treatment. The use of glucocorticoids for the treatment of sCAP has been a focus of discussion in the medical community because of their potential benefits and safety concerns. A literature review showed that the benefits of glucocorticoids in the treatment of sCAP may be related to factors such as oxygenation index, high CRP levels, shock, non-influenza, female gender, early application, and hydrocortisone. The application of glucocorticoids in the treatment of sCAP needs to be considered on an individual basis, weighing the potential benefits and risks, and monitoring and preventing possible side effects.
- 1 June 2024
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 326 (6) , C1563-C1572
Ox-LDL-induced CD80+ macrophages expand pro-atherosclerotic NKT cells via CD1d in atherosclerotic mice and hyperlipidemic patients
This work proposed the ox-LDL-CD80+ monocyte/macrophage-CD1d-NKT cell-IFN-γ axis in the progression of atherosclerosis. The proinflammatory IFN-γ+ NKT cells are closely related to CD1d+CD80+ monocytes in hyperlipidemic patients. Inhibiting CD80+ macrophages to present lipid antigens to NKT cells through CD1d blocking may be a new therapeutic target for atherosclerosis.
- 1 June 2024
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 326 (6) , C1563-C1572
Ox-LDL-induced CD80+ macrophages expand pro-atherosclerotic NKT cells via CD1d in atherosclerotic mice and hyperlipidemic patients
This work proposed the ox-LDL-CD80+ monocyte/macrophage-CD1d-NKT cell-IFN-γ axis in the progression of atherosclerosis. The proinflammatory IFN-γ+ NKT cells are closely related to CD1d+CD80+ monocytes in hyperlipidemic patients. Inhibiting CD80+ macrophages to present lipid antigens to NKT cells through CD1d blocking may be a new therapeutic target for atherosclerosis.